Cargando…
Cancer stem cell targeted therapy: progress amid controversies
Although cancer stem cells have been well characterized in numerous malignancies, the fundamental characteristics of this group of cells, however, have been challenged by some recent observations: cancer stem cells may not necessary to be rare within tumors; cancer stem cells and non-cancer stem cel...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792551/ https://www.ncbi.nlm.nih.gov/pubmed/26496035 |
_version_ | 1782421261428719616 |
---|---|
author | Wang, Tao Shigdar, Sarah Gantier, Michael P. Hou, Yingchun Wang, Li Li, Yong Shamaileh, Hadi Al Yin, Wang Zhou, Shu-Feng Zhao, Xinhan Duan, Wei |
author_facet | Wang, Tao Shigdar, Sarah Gantier, Michael P. Hou, Yingchun Wang, Li Li, Yong Shamaileh, Hadi Al Yin, Wang Zhou, Shu-Feng Zhao, Xinhan Duan, Wei |
author_sort | Wang, Tao |
collection | PubMed |
description | Although cancer stem cells have been well characterized in numerous malignancies, the fundamental characteristics of this group of cells, however, have been challenged by some recent observations: cancer stem cells may not necessary to be rare within tumors; cancer stem cells and non-cancer stem cells may undergo reversible phenotypic changes; and the cancer stem cells phenotype can vary substantially between patients. Here the current status and progresses of cancer stem cells theory is illustrated and via providing a panoramic view of cancer therapy, we addressed the recent controversies regarding the feasibility of cancer stem cells targeted anti-cancer therapy. |
format | Online Article Text |
id | pubmed-4792551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-47925512016-03-29 Cancer stem cell targeted therapy: progress amid controversies Wang, Tao Shigdar, Sarah Gantier, Michael P. Hou, Yingchun Wang, Li Li, Yong Shamaileh, Hadi Al Yin, Wang Zhou, Shu-Feng Zhao, Xinhan Duan, Wei Oncotarget Review Although cancer stem cells have been well characterized in numerous malignancies, the fundamental characteristics of this group of cells, however, have been challenged by some recent observations: cancer stem cells may not necessary to be rare within tumors; cancer stem cells and non-cancer stem cells may undergo reversible phenotypic changes; and the cancer stem cells phenotype can vary substantially between patients. Here the current status and progresses of cancer stem cells theory is illustrated and via providing a panoramic view of cancer therapy, we addressed the recent controversies regarding the feasibility of cancer stem cells targeted anti-cancer therapy. Impact Journals LLC 2015-10-19 /pmc/articles/PMC4792551/ /pubmed/26496035 Text en Copyright: © 2015 Wang et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Wang, Tao Shigdar, Sarah Gantier, Michael P. Hou, Yingchun Wang, Li Li, Yong Shamaileh, Hadi Al Yin, Wang Zhou, Shu-Feng Zhao, Xinhan Duan, Wei Cancer stem cell targeted therapy: progress amid controversies |
title | Cancer stem cell targeted therapy: progress amid controversies |
title_full | Cancer stem cell targeted therapy: progress amid controversies |
title_fullStr | Cancer stem cell targeted therapy: progress amid controversies |
title_full_unstemmed | Cancer stem cell targeted therapy: progress amid controversies |
title_short | Cancer stem cell targeted therapy: progress amid controversies |
title_sort | cancer stem cell targeted therapy: progress amid controversies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792551/ https://www.ncbi.nlm.nih.gov/pubmed/26496035 |
work_keys_str_mv | AT wangtao cancerstemcelltargetedtherapyprogressamidcontroversies AT shigdarsarah cancerstemcelltargetedtherapyprogressamidcontroversies AT gantiermichaelp cancerstemcelltargetedtherapyprogressamidcontroversies AT houyingchun cancerstemcelltargetedtherapyprogressamidcontroversies AT wangli cancerstemcelltargetedtherapyprogressamidcontroversies AT liyong cancerstemcelltargetedtherapyprogressamidcontroversies AT shamailehhadial cancerstemcelltargetedtherapyprogressamidcontroversies AT yinwang cancerstemcelltargetedtherapyprogressamidcontroversies AT zhoushufeng cancerstemcelltargetedtherapyprogressamidcontroversies AT zhaoxinhan cancerstemcelltargetedtherapyprogressamidcontroversies AT duanwei cancerstemcelltargetedtherapyprogressamidcontroversies |